In an effort to return the thread's attention back to Zonagen and away from both the self-interested posts of a paid stock promoter and the Pluvia debate which has been discussed ad nauseum elsewhere, I'd like to point out that Zonagen filed an 8-K today. You may examine the filing yourself at the following useful site: freeedgar.com
Nothing particularly new in this filing, just the official SEC form announcing the material event of the licensing arrangement with SGP. Included in the filing is also the formerly released press announcement from November 17th. I'll cite a portion of that included release in order to try to recenter the thread on more profitable, fact based, discussion.
Anaxagoras
~~~~~~~~~~~~~~
<<Madison, N.J. and The Woodlands, Texas, November 17, 1997 -- Schering-Plough
Corporation (NYSE: SGP) and Zonagen, Inc. (Nasdaq: ZONA; Pacific: ZNG) today
announced an agreement giving Schering-Plough exclusive worldwide marketing
rights to Vasomax(TM), Zonagen's novel, immediate-release, oral formulation of
phentolamine mesylate, in late-stage development for the treatment of male
erectile dysfunction.
Under the agreement, Schering-Plough will pay Zonagen an upfront payment of $10
million with subsequent milestone payments once specified regulatory goals are
achieved. With the upfront payment and if all milestones are met, the agreement
is valued at $57.5 million, exclusive of royalties. Zonagen will receive
escalating royalties on all product sales. >> |
